[go: up one dir, main page]

DOP2012000170A - Proceso para la fabricacion de un agente farmaceuticamante activo - Google Patents

Proceso para la fabricacion de un agente farmaceuticamante activo

Info

Publication number
DOP2012000170A
DOP2012000170A DO2012000170A DO2012000170A DOP2012000170A DO P2012000170 A DOP2012000170 A DO P2012000170A DO 2012000170 A DO2012000170 A DO 2012000170A DO 2012000170 A DO2012000170 A DO 2012000170A DO P2012000170 A DOP2012000170 A DO P2012000170A
Authority
DO
Dominican Republic
Prior art keywords
manufacture
active pharmaceutically
pharmaceutically agent
agent
active
Prior art date
Application number
DO2012000170A
Other languages
English (en)
Inventor
Svend Treppendahl
Frans Therkelsen
Michael Harold Rock
Original Assignee
H Lundbeck & Co As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck & Co As filed Critical H Lundbeck & Co As
Publication of DOP2012000170A publication Critical patent/DOP2012000170A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Se revelan aquí los procesos para la preparación de un agente farmacéuticamente activo y las saies farmacéuticamente aceptables del mismo.
DO2012000170A 2009-12-23 2012-06-18 Proceso para la fabricacion de un agente farmaceuticamante activo DOP2012000170A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28953009P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
DOP2012000170A true DOP2012000170A (es) 2012-08-31

Family

ID=43567689

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000170A DOP2012000170A (es) 2009-12-23 2012-06-18 Proceso para la fabricacion de un agente farmaceuticamante activo

Country Status (38)

Country Link
US (3) US8461353B2 (es)
EP (1) EP2516394B1 (es)
JP (2) JP5864435B2 (es)
KR (2) KR101873182B1 (es)
CN (2) CN102656146B (es)
AR (1) AR079580A1 (es)
AU (1) AU2010335659B2 (es)
BR (1) BR112012015749A2 (es)
CA (1) CA2785440C (es)
CL (1) CL2012001725A1 (es)
CR (1) CR20120316A (es)
CY (1) CY1118032T1 (es)
DK (1) DK2516394T3 (es)
DO (1) DOP2012000170A (es)
EA (1) EA021440B1 (es)
ES (1) ES2575666T3 (es)
GE (1) GEP20146078B (es)
HK (2) HK1174921A1 (es)
HR (1) HRP20160518T1 (es)
HU (1) HUE028806T2 (es)
IL (2) IL220329A (es)
MA (1) MA33945B1 (es)
ME (1) ME02401B (es)
MX (1) MX2012007078A (es)
MY (1) MY159251A (es)
NZ (2) NZ625798A (es)
PH (1) PH12012501258A1 (es)
PL (1) PL2516394T3 (es)
PT (1) PT2516394E (es)
RS (1) RS54820B1 (es)
SG (1) SG181910A1 (es)
SI (1) SI2516394T1 (es)
SM (1) SMT201600166B (es)
TN (1) TN2012000279A1 (es)
TW (1) TW201139370A (es)
UA (1) UA111584C2 (es)
WO (1) WO2011076212A2 (es)
ZA (1) ZA201305936B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JO3639B1 (ar) * 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
CN104130174A (zh) * 2014-07-30 2014-11-05 天津市斯芬克司药物研发有限公司 一种吲唑衍生物及其制备方法
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
WO2016091997A1 (en) 2014-12-12 2016-06-16 H. Lundbeck A/S A process for the manufacture of idalopirdine
CN104529865B (zh) * 2014-12-12 2017-02-01 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
MA41148A (fr) * 2014-12-12 2017-10-17 H Lundbeck As Procédé de fabrication d'idalopirdine
CN108271369A (zh) * 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
WO2017174691A1 (en) 2016-04-08 2017-10-12 H. Lundbeck A/S A process for the manufacture of idalopirdine via hydrogenation of an imine
EP3333154A1 (en) * 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist
JP2022515610A (ja) * 2018-12-27 2022-02-21 エフ．ホフマン－ラ ロシュ アーゲー ｅｘｏ－ｔｅｒｔ－ブチルＮ－（３－アザビシクロ［３．２．１］オクタン－８－イル）カルバミン酸塩の調製のためのプロセス

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042685A (en) 1962-07-03 Process of making g-fluoro tryptamine
GB846675A (en) * 1958-04-18 1960-08-31 Lab Francais Chimiotherapie Process for the production of a tryptamine derivative
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
US5777166A (en) 1993-12-28 1998-07-07 Rhone-Poulenc Chimie Process for the catalytic hydrogenation of nitriles to amines in the presence of a catalyst of doped raney nickel type
JP2851439B2 (ja) 1993-12-28 1999-01-27 ローヌープーラン シミ ニトリルを水素化してアミンにするための触媒の調製方法及びこの触媒の水素化における用途
US5869653A (en) 1997-10-30 1999-02-09 Air Products And Chemicals, Inc. Hydrogenation of nitriles to produce amines
WO1999022561A2 (en) 1997-10-31 1999-05-14 Koninklijke Philips Electronics N.V. A method and apparatus for audio representation of speech that has been encoded according to the lpc principle, through adding noise to constituent signals therein
US6156694A (en) 1998-11-05 2000-12-05 E. I. Dupont De Nemours & Company Raney cobalt catalyst and a process for hydrogenating organic compounds using said catalyst
NZ527815A (en) 2001-03-29 2005-05-27 Lilly Co Eli N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor
US7084154B2 (en) * 2003-02-11 2006-08-01 Pharmacopeia Drug Disclovery, Inc. 2-(aminomethyl) arylamide analgesics
FR2866335B1 (fr) 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
JP2006169113A (ja) * 2004-12-10 2006-06-29 Dainippon Sumitomo Pharma Co Ltd インドール類の合成方法および合成中間体
US20090203577A1 (en) 2005-12-15 2009-08-13 Exelixis, Inc. Azepinoindole Derivatives As Pharmaceutical Agents
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
WO2010036362A1 (en) * 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
CN101531624A (zh) * 2009-04-08 2009-09-16 大连凯飞精细化工有限公司 6-氟吲哚-3-乙腈的合成方法
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent

Also Published As

Publication number Publication date
AU2010335659A1 (en) 2012-07-05
HUE028806T2 (en) 2017-01-30
PT2516394E (pt) 2016-06-07
JP5864435B2 (ja) 2016-02-17
IL220329A (en) 2016-03-31
CR20120316A (es) 2012-08-16
CA2785440A1 (en) 2011-06-30
IL231141A0 (en) 2014-03-31
EA201290552A1 (ru) 2012-12-28
NZ625798A (en) 2014-10-31
ME02401B (me) 2016-09-20
DK2516394T3 (en) 2016-06-13
HK1196352A1 (en) 2014-12-12
KR20170125417A (ko) 2017-11-14
MY159251A (en) 2016-12-30
WO2011076212A2 (en) 2011-06-30
RS54820B1 (sr) 2016-10-31
KR101796330B1 (ko) 2017-11-09
CY1118032T1 (el) 2017-05-17
TN2012000279A1 (en) 2013-12-12
KR20120112480A (ko) 2012-10-11
SMT201600166B (it) 2016-07-01
KR101873182B1 (ko) 2018-06-29
BR112012015749A2 (pt) 2015-09-15
US8461353B2 (en) 2013-06-11
NZ600639A (en) 2014-07-25
AU2010335659B2 (en) 2015-05-21
US8901318B2 (en) 2014-12-02
GEP20146078B (en) 2014-04-10
JP6195605B2 (ja) 2017-09-13
UA111584C2 (uk) 2016-05-25
IL231141A (en) 2016-03-31
SG181910A1 (en) 2012-08-30
EP2516394B1 (en) 2016-03-16
HK1174921A1 (en) 2013-06-21
ZA201305936B (en) 2015-09-30
HRP20160518T1 (hr) 2016-06-03
US9382205B2 (en) 2016-07-05
CN102656146A (zh) 2012-09-05
TW201139370A (en) 2011-11-16
SI2516394T1 (sl) 2016-07-29
EP2516394A2 (en) 2012-10-31
CN102656146B (zh) 2014-12-17
PL2516394T3 (pl) 2016-09-30
MX2012007078A (es) 2012-07-20
IL220329A0 (en) 2012-08-30
MA33945B1 (fr) 2013-01-02
CN103694161B (zh) 2015-09-09
US20150080584A1 (en) 2015-03-19
CA2785440C (en) 2018-05-01
JP2013515683A (ja) 2013-05-09
JP2016117734A (ja) 2016-06-30
ES2575666T3 (es) 2016-06-30
US20130245281A1 (en) 2013-09-19
WO2011076212A3 (en) 2011-08-11
CL2012001725A1 (es) 2012-11-30
CN103694161A (zh) 2014-04-02
PH12012501258A1 (en) 2013-02-04
US20110152539A1 (en) 2011-06-23
AR079580A1 (es) 2012-02-01
EA021440B1 (ru) 2015-06-30

Similar Documents

Publication Publication Date Title
DOP2012000170A (es) Proceso para la fabricacion de un agente farmaceuticamante activo
CR20140512A (es) Dispositivos y metodos para la fabricación de aditivos de componentes de implante
CR20140200A (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
UY34542A (es) ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
MX370543B (es) Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
EP2762012A4 (en) SMALL MOLECULE ACTIVE DONKEY GELATIN MIXTURE AND PREPARATION METHOD AND APPLICATION THEREOF
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
GT201500069A (es) Piridinonas bicìclicas novedosas
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
GT201400085A (es) Profármaco de adrenomedulina basado en polietilenglicol y su uso
CR20140334A (es) Forma galénica divisible que permite una liberación modificada del principio activo
MY191875A (en) Solid dosage form
IN2013MU00711A (es)
ES2666382T8 (es) Ortesis activa para la rehabilitación neurológica del movimiento de los miembros inferiores, sistema que comprende dicha órtesis y proceso para poner en funcionamiento dicho sistema
WO2012103226A3 (en) Bendamustine formulations
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
EP3395943A4 (en) PROCESS FOR PRODUCING TISSUE / ORGANS BY MEANS OF BLOOD CELLS
MY162688A (en) Oral care compositions
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
IN2013MU01985A (es)
ECSP13012613A (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
MX2016005227A (es) Polipéptidos de acción prolongada y métodos para su producción y administración.